Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 9/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.46 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.46 |
| ▸ | ABL2 | P42684 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1227713 | 0.77 | CYP1A2 (0.60) | NPC1RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL29699887 | 0.77 | CYP1A2 (0.60) | NPC1RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL27917128 | 0.77 | CYP1A2 (0.60) | NPC1RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL30487734 | 0.75 | CYP1A2 (0.58) | NPC1RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL6627903 | 0.74 | TGFBR1 (0.67) | NPC1RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL3428078 | 0.74 | GAK (0.42) | ACVR1 | |
| SCHEMBL674356 | 0.73 | NISCH (0.42) | NPC1KDM4EALDH1A1HPGDMAPK1 | |
| SCHEMBL30589021 | 0.73 | NISCH (0.42) | NPC1KDM4EALDH1A1HPGDMAPK1 | |
| SCHEMBL27596511 | 0.73 | NISCH (0.42) | NPC1KDM4EALDH1A1HPGDMAPK1 | |
| SCHEMBL9194481 | 0.72 | CYP1A2 (0.53) | NPC1RAB9AKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020248908-A1 | BIFUNCTIONAL IMMUNOMODULATOR, AND PHARMACEUTICALLY ACCEPTABLE SALT AND PHARMACEUTICAL COMPOSITION THEREOF | 中国科学院广州生物医药与健康研究院 | 2020-12-17 | — | — | WO | disclosed |
| CN-102015678-A | Fused pyridine active substances as c-Met inhibitors | HOFFMANN LA ROCHE | 2011-04-13 | — | — | CN | disclosed |
| US-20110053935-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053935-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| EP-2247584-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | F. Hoffmann-La Roche AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009093049-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009093049-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-30 | — | — | WO | disclosed |
| EP-1730116-B1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070167507-A1 | 4-Carbox pyrazole derivatives useful as anti-viral agents | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | US | disclosed |
| CN-1960976-A | 4-carbox pyrazole derivates useful as anti-viral agents | SMITHKLINE BEECHAM CORP (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1730116-A1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005092863-A1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
| US-5622914-A | APPLYING A PYRAZOLYL OR IMIDAZOLYL QUINOLINE DERIVATIVE; PLANT DISEASE CONTROL | NIHON BAYER AGROCHEM K.K. (JP) | 1997-04-22 | — | — | US | disclosed |
| EP-0703234-A1 | Microbicidal Quinoline Derivatives | NIHON BAYER AGROCHEM K.K. (JP) | 1996-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053935-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | MET, ROS1, ABL1 | NPC1 2302/4885RAB9A 1454/4885KDM4E 826/4885 |
| US-20070167507-A1 | 4-Carbox pyrazole derivatives useful as anti-viral agents | HAVCR2, RPL35, ZC3HAV1L | NPC1 352/4885RAB9A 1879/4885KDM4E 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.